LY2140023
- Generic Name
- LY2140023
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 3V85EZ3KFQ
- Background
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications wo...
- Indication
Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of LY2140023 in Healthy Participants
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Denovo Biopharma LLC
- Registration Number
- NCT01659177
- Locations
- 🇨ðŸ‡
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allschwil, Switzerland
A Study of LY2140023 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01637142
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of LY2140023 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 27
- Registration Number
- NCT01609218
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 86
- Registration Number
- NCT01606436
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
A Study of LY2979165 and LY2140023 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT01524237
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, UK, United Kingdom
A Study of LY2140023 in Hepatically-Impaired Participants
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 37
- Registration Number
- NCT01475136
- Locations
- ðŸ‡ðŸ‡º
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balatonfüred, Hungary
A Physical Dependence Study in Schizophrenia
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 123
- Registration Number
- NCT01452919
- Locations
- 🇬🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tripoli, Greece
The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01440478
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom
A Study of Safety and Tolerability in Subjects With Schizophrenia
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 75
- Registration Number
- NCT01354353
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01328093
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.